CTMX · Cytomx Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $69.57M | $100.36M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M | $112.94M |
| SG&A | $29.84M | $29.73M | $30.02M | $42.85M | $39.16M | $36.03M |
| Total Operating Expenses | $98.56M | $113.11M | $107.70M | $154.50M | $153.35M | $148.97M |
| D&A | $1.20M | $1.60M | $2.00M | $2.30M | $2.60M | $2.40M |
| Operating Income | ($22.36M) | $25.00M | ($6.48M) | ($101.33M) | ($83.78M) | ($48.60M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $238.0K | $224.0K | $3.89M | $0 | $0 | ($13.91M) |
| Net Income | ($17.37M) | $31.87M | ($569.0K) | ($99.32M) | ($83.61M) | ($32.88M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.67M | $38.05M | $17.17M | $193.65M | $205.53M | $191.86M |
| Accounts Receivable | $2.01M | $3.10M | $3.43M | $35.99M | $790.0K | $798.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.30M | $1.09M | $1.46M | $2.81M | $2.82M | $3.00M |
| Current Assets | $143.92M | $107.31M | $182.94M | $237.10M | $310.30M | $324.01M |
| Total Assets | $151.57M | $120.53M | $201.79M | $260.89M | $339.41M | $358.66M |
| Current Liabilities | $46.62M | $85.77M | $155.91M | $152.61M | $106.32M | $100.92M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $52.56M | $120.99M | $249.24M | $346.64M | $250.03M | $308.86M |
| Stockholders' Equity | $99.01M | ($456.0K) | ($47.45M) | ($85.75M) | $89.38M | $49.80M |
| Retained Earnings | ($711.95M) | ($691.58M) | ($723.45M) | ($722.88M) | ($533.72M) | ($450.12M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($75.59M) | ($86.23M) | ($56.03M) | ($110.79M) | ($119.03M) | $5.26M |
| Investing Cash Flow | ($59.74M) | $99.70M | ($150.67M) | $98.26M | $22.49M | ($18.72M) |
| Financing Cash Flow | $110.45M | $7.52M | $30.23M | $648.0K | $110.21M | $16.89M |
| CapEx | $220.0K | $310.0K | $840.0K | $1.74M | $1.61M | $2.31M |
| Free Cash Flow | ($75.81M) | ($86.54M) | ($56.88M) | ($112.53M) | ($120.64M) | $2.95M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -29.3% | 18.1% | -6.4% | -190.6% | -120.4% | -48.4% |
| EBITDA margin | -27.8% | 19.3% | -4.4% | -186.3% | -116.7% | -46.0% |
| Net margin | -22.8% | 23.1% | -0.6% | -186.8% | -120.2% | -32.8% |
| Free cash flow margin | -99.5% | -62.7% | -56.2% | -211.7% | -173.4% | 2.9% |
| FCF / Net income | 4.36 | -2.72 | 99.96 | 1.13 | 1.44 | -0.09 |
| R&D / Revenue | 90.2% | 60.4% | 76.7% | 210.0% | 164.1% | 112.5% |
| SG&A / Revenue | 39.2% | 21.5% | 29.7% | 80.6% | 56.3% | 35.9% |
| Effective tax rate | - | 0.7% | 117.1% | - | - | - |
| Return on assets | -11.5% | 26.4% | -0.3% | -38.1% | -24.6% | -9.2% |
| Return on equity | -17.5% | -6988.8% | 1.2% | 115.8% | -93.5% | -66.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.09 | 1.25 | 1.17 | 1.55 | 2.92 | 3.21 |
| Quick ratio | 3.09 | 1.25 | 1.17 | 1.55 | 2.92 | 3.21 |
| Cash ratio | 0.27 | 0.44 | 0.11 | 1.27 | 1.93 | 1.90 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.53 | -264.33 | -4.25 | -3.04 | 3.80 | 7.20 |
| Liabilities / Assets | 0.35 | 1.00 | 1.24 | 1.33 | 0.74 | 0.86 |
| Efficiency | ||||||
| Asset turnover | 0.50 | 1.15 | 0.50 | 0.20 | 0.20 | 0.28 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 10d | 8d | 12d | 247d | 4d | 3d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 5.9x | - | - | - | 2.2x | - |
| P / S | 7.7x | 0.6x | 1.1x | 2.0x | 2.9x | - |
| EV / EBITDA | - | 1.9x | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -44.8% | 36.4% | 90.4% | -23.6% | -30.7% | 74.6% |
| Revenue CAGR (3y) | 12.8% | 25.7% | 0.3% | -2.6% | 5.4% | 11.9% |
| Revenue CAGR (5y) | -5.4% | 19.2% | 11.2% | -5.8% | 35.8% | 157.4% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 93.6% | -21.0% | -72.4% | 56.2% |
| Net income growth (YoY) | - | - | 99.4% | -18.8% | -154.2% | 67.8% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 12.4% | -52.2% | 49.5% | 6.7% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 99.0% | 44.7% | - | 79.5% | -2.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2019-12-31.
Product / service
$17.40M totalThird And Fourth Targets$17.40M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.68
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CytomX Therapeutics against the 5 most active filers in the same SIC group.